EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
about
Crizotinib resistance: implications for therapeutic strategiesTackling ALK in non-small cell lung cancer: the role of novel inhibitorsImmune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer TreatmentPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceFocus on Nivolumab in NSCLCCurrent state of immunotherapy for non-small cell lung cancer.Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Recent Advances in Targeting ROS1 in Lung Cancer.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Atezolizumab for the treatment of non-small cell lung cancer.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Peptide vaccines in cancer-old concept revisited.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Targeting ALK: Precision Medicine Takes on Drug Resistance.EGFR TKI combination with immunotherapy in non-small cell lung cancer.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.Current status of research and treatment for non-small cell lung cancer in never-smoking females.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures.Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs.Molecular diagnostics of lung cancer in the clinic.
P2860
Q26738381-4B0A6201-C8AC-4F6F-952F-3B7E1F4E1253Q26740329-373AC506-796D-482B-BC39-20B67D51B046Q28069424-BFDE46CA-77A4-447D-9DF5-3366ECE65259Q28071903-D7C25EC1-0095-4DE7-BB81-F4C6CCD60490Q28073759-CFABF4C9-632E-4410-BF97-9F0735240A74Q33645595-9FF8B44E-46FB-4812-AF29-F3B76D0B7C18Q36352476-905F063F-25EF-47F5-B91C-D973D437B11DQ36400381-D380A722-CEB3-40E6-8D98-501A61DAD541Q37277198-2EE38225-E825-4E8C-B4B1-4781B7093C8DQ37702430-24E2E8A0-7945-403D-B7D7-E107CE47677AQ37702792-2886A37B-B27F-4A22-BE4E-152B7C6837A5Q38635259-C3BD62BF-A546-45D2-B510-2DF03A336207Q38640765-C6B36F41-D498-41AE-B5DF-2DB64D57A531Q38663460-5947DFF2-22D3-47A7-BC9D-5DD7F6EE2E90Q38675969-26C96FB5-F1A0-46EC-A0F8-E7FF5FC39C09Q38720801-3A5203B2-1ACD-4E64-AB36-D597B2CD552DQ38746756-59BC4125-7EB9-401D-ACA1-61780F00EB01Q38769610-A22DD842-F57E-47C1-87A4-0A817BA26D3DQ38827684-35C694F5-A541-45BA-945C-C35F3D536464Q38830398-5F6E7493-4903-44BB-81A7-E3CFC0E0C854Q38840383-ECD058AA-3A2B-420B-8592-9B54C36D2AEAQ38995416-60972AEC-2F18-46A6-8764-EF2EFB4D07AFQ39002233-1DF7379C-CACB-416F-8FC5-D80790E41765Q39027385-04AEEB0F-E6D1-4D75-882F-AD2FD0146409Q39035351-7CDF1D7A-DC8C-4CB0-B38D-13A184C36023Q39095285-ACFFACC0-0B11-4CFB-9BF2-D3F956C2D407Q39103431-ED479B40-E235-44E6-AB3A-3CEB62DBCA83Q39167752-40B8E89C-FBE9-4C92-B0FC-1360713FAD7AQ39288360-2140CF47-0D1E-4F7F-BF5C-CDEA3DD8BE4BQ39298725-2E79FA24-B527-4647-9683-FDAD3FB5564FQ40496586-2CD7F224-3D65-475C-852D-937FBD278517Q41201725-C5AC5ACB-4F85-42C5-A049-56B3CADD9777Q41306256-12F7EA9D-7C3D-4456-8429-D5896EDEB86BQ41899044-8E2D8166-6826-4E6C-BA37-69EE2E0B36C2Q42004900-795D38E8-2E1F-4990-8074-362C774229FBQ42314661-E7D18D31-2E15-4886-B818-5982135CFC3EQ42362351-862215ED-BA6C-4169-BC4D-40D310E345A4Q42644265-2F38FBC4-43AA-46B5-82BB-5821F8224C68Q43259078-08BE2EAB-87D4-4936-9DE2-8A5DB24E4510Q43690882-57642246-9C3B-44D6-AB8B-069BD0B3DE82
P2860
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
EGFR Mutations and ALK Rearran ...... cer: A Retrospective Analysis.
@en
type
label
EGFR Mutations and ALK Rearran ...... cer: A Retrospective Analysis.
@en
prefLabel
EGFR Mutations and ALK Rearran ...... cer: A Retrospective Analysis.
@en
P2093
P2860
P1476
EGFR Mutations and ALK Rearran ...... ncer: A Retrospective Analysis
@en
P2093
Alice T Shaw
Anna F Farago
Beow Y Yeap
Christopher G Azzoli
Emily Howe
James R Stone
Jeffrey A Engelman
Justin F Gainor
Katherine R Schultz
Lecia V Sequist
P2860
P304
P356
10.1158/1078-0432.CCR-15-3101
P407
P50
P577
2016-05-25T00:00:00Z